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Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium respon- 
sable for several difficult-to-treat infections in humans. It is also called oxacillin-resistant 
Staphylococcus aureus (ORSA). MRSA is any strain o f Staphylococcus aureus that has developed, 
through the process o f natural selection, resistance to beta-lactam antibiotics, which include the 
penicillins (methicillin, dicloxacillin, nafcillin, oxacillin, etc.) and the cephalosporins. Strains 
unable to resist these antibiotics are classified as methicillin-sensitive Staphylococcus aureus, or 
MSSA. The evolution o f  such resistance does not cause the organism to be more intrinsically 
virulent than strains o f  Staphylococcus aureus that have no antibiotic resistance, but resistance does 
make MRSA infection more difficult to treat with standard types o f  antibiotics and thus more 
dangerous. MRSA is especially troublesome in hospitals, prisons and nursing homes, where patients 
with open wounds, invasive devices, and weakened immune systems are at greater risk o f  infection 
than the general public. This study provides information about the aggression and dominance o f  this 
bacteria, as well the incidence in surgical wards o f  Republican Clinical Hospital.
Materials and methods: The study was conducted on the principle o f  bacteriological analysis 
o f  139 samples with Staphylococcus aureus, from the Register o f  laboratory investigations, Form 
no. 250 / e, approved by Ministry o f Health o f  the Republic o f  Moldova, no. 828 o f  31.10.2011. The 
data obtained were characterized and interpreted statistically: we evaluated the total number o f  
cases o f  MRSA infection and its incidence comparing with the total number o f  cases.
The result of discussion: In a study o f  Republican Clinic Hospital, Bacteriological 
Laboratory, during 2013 were registered 139 cases o f  infection with S.aureus, 39 o f  them were 
found to be MRSA, that represents approximately 28% o f  all staphylococcal infections. Nearly half 
o f  the samples with MRSA belonged to patients hospitalized in the department o f  General Surgery - 
48%, Otorhinolaryngology - 18%, Clinic -13%, and Thoracic Surgery - 11%.
Conclusion: MRSA is a „super-bacteria" extensively studied in the present, with a strong 
resistance to methicillin / oxacillin, frequently hospital infection acquired resistance, the most 
common in the departments o f General Surgery and ENT. As in other countries, cases o f  MRSA are 
frequent in Moldova, unfortunately they are increasing.
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Introduction: Arginine vasopressin (AVP) is the major physiological regulator o f renal water 
excretion and blood volume. The AVP pathways o f V ia  Receptor-mediated vasoconstriction and V2 
Receptor-induced water retention represent a potentially attractive target for therapy o f  congestive heart 
failure, even more that there is a big class o f patients which develop resistance at diuretics.
Purpose and Objectives: Highlighting the importance o f  Arginine vasopressin in the evolution 
o f the congestive heart failure and the potential therapeutic benefit o f the AVP receptor antagonists.
Materials and Methods: The presentation represents an extensive literature review and is based 
on up-to-date information extracted from 4clinical trials: EVEREST, SALT 1 and 2, OPTIMIZE-HF.
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